Yearly Archives: "2016"

Genentech Results from Survey that Shows Everyday Impact of Unpredictable MS Symptoms
Jesse met his wife at a college dance. When they first started dating, she told him that she had multiple sclerosis (MS), a disease of the [...]
Men & Women Seem to Differ in Genetic Susceptibility to MS & its Progression in Study
Researchers in Russia found for a first time an association between variants in GAL, a gene that codes for the galanin protein, and [...]
Immune System May Harbor Natural Way of Fighting MS, Other Autoimmune Diseases
A variant in the TYK2 gene, which encodes an immune system protein, may work to protect people from autoimmune disorders, including [...]
Posture Difficulties in MS Linked to Areas of Nervous System Most Damaged by Disease
Posture control is a complex skill, requiring different areas of the nervous system to work well and to work together — but the damage [...]
‘Rare’ Molecule in Immune System is Common and May be Part of What Goes Wrong in MS
Researchers have discovered that a type of immune molecule — called “spliced epitopes,” once believed to be very rare  — in fact [...]
Selective Manipulation of Specific Receptors May Pave Way for New MS Therapies
Mouse experiments with compounds having opposite actions on two receptors for TNF (tumor necrosis factor) — a key factor in [...]
Multiple Sclerosis Drug Could Reverse Physical Symptoms
Multiple sclerosis (MS) is estimated to affect 2.3 million individuals worldwide. The majority of people with MS are initially diagnosed [...]
Multiple Sclerosis Research Finds Running ‘Could Help Prevent’ Notorious Disease
For years, health advocates have urged the public to abandon their sedentary lifestyle and adopt a more active daily routine. Recently, a [...]
United Spinal Association offering range of materials at exhibit booth at CMSC 2016 Annual Meeting
The United Spinal Association, a nonprofit focused on improving the quality of life for people with spinal cord injuries and disorders [...]
Daclizumab Approved (zinbryta tm) for Relapsing Forms of Multiple Sclerosis
The DECIDE trial compared daclizumab 150mg subcutaneous injection every 4 weeks with interferon (INF) beta-1a (Avonex) 30mcg once weekly [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM